Supriya Lifescience aims up to Rs 1,600 crore revenue in next three years

17 Dec 2025 Evaluate

Supriya Lifescience is eyeing up to Rs 1,600 crore revenue from its Lote MIDC in Ratnagiri and Ambernath facilities in the next three years. The company's Patalganga facility will take 2.5-3 years to become operational.

The company had a capex of Rs 160 crore for setting up its Ambernath facility, and Rs 350 crore for the Patalganga unit, which will be spent in a phased manner.

Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.

Supriya Lifescience Share Price

737.80 -5.25 (-0.71%)
13-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.80
Dr. Reddys Lab 1190.35
Cipla 1447.60
Zydus Lifesciences 900.25
Lupin 2176.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×